Vivo Bio Tech Ltd.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 July 2026, providing investors with the latest insights into the stock’s performance and outlook.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended June 2026, signalling a pause in its recent downward trend. Despite achieving its highest quarterly net sales and improved operational metrics, the company continues to grapple with margin pressures and a subdued return on capital employed, reflecting ongoing challenges in its business environment.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 July 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Vivo Bio Tech Limited, a contract research organisation specialising in drug development services, reported a concerning Q1 FY27 performance with net profit collapsing 85.82% year-on-year to ₹0.19 crores despite modest revenue growth. The micro-cap pharmaceutical services company, with a market capitalisation of ₹54.00 crores, saw its stock decline 4.72% to ₹24.00 following the results announcement, extending its bearish trend that has persisted since June 2026.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 June 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 30 June 2026, providing investors with the latest view of the company’s position in the market.

Vivo Bio Tech Ltd. is rated Strong Sell by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a marked deterioration in its financial performance for the quarter ended March 2026. Despite achieving its highest quarterly net sales to date, the company’s profitability and operational efficiency have sharply declined, prompting a downgrade to a Strong Sell rating by MarketsMOJO as of 1 June 2026.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 1 June 2026. This adjustment reflects deteriorating fundamentals, worsening technical indicators, and a bleak financial trend, signalling heightened risk for investors amid sustained underperformance against benchmarks.

Vivo Bio Tech Ltd., a contract research organisation specialising in drug development and discovery services, reported a shocking net loss of ₹5.16 crores in Q4 FY26, a dramatic reversal from the ₹1.25 crore profit in the previous quarter. The loss, driven by an extraordinary tax charge of ₹5.41 crores representing a staggering 2,164.00% effective tax rate, overshadowed an otherwise improving operational performance with revenue reaching a quarterly high of ₹14.20 crores. The stock plunged 10.67% to ₹24.62 following the results announcement, reflecting investor concern over the deteriorating profitability despite sequential revenue growth of 5.11%.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 26 May 2026. This change is primarily driven by a shift in technical indicators, despite ongoing challenges in financial performance and valuation metrics. The company’s stock price currently trades at ₹27.18, down 1.84% on the day, reflecting mixed signals from market participants.

Vivo Bio Tech Ltd., a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 21 May 2026. This revision reflects deteriorating technical indicators, stagnant financial performance, and subdued valuation metrics, signalling heightened risks for investors amid a challenging market environment.

Vivo Bio Tech Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Vivo Bio Tech Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 15 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 May 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and technical outlook.